Full-Time

Vice President

Global Business Unit Head Oncology, Market Access

Posted on 9/9/2025

Deadline 9/26/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$347.7k - $421.4k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Hybrid

Hybrid work model with at least 50% onsite presence required.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Undergraduate degree required, an advanced degree (MBA and/or PhD) degree highly desired
  • Minimum of 15 to 20 years' experience with a strong track record in Market Access, Pricing or HEOR in a Global/WW or large country market
  • Demonstrated ability to lead and leverage high performing, highly experienced cross-functional teams through complex decisions to deliver results, and develop talent
  • Understanding of the current and evolving global market access, pricing, and HEOR environment for Oncology products
  • Solid understanding of competitors in the Oncology space; familiarity with top KOLs and their clinical beliefs in the core disease areas a plus
  • Previous leadership experience in launch / commercialization required, with demonstrable results in achieving positive HTA results across WW markets
  • Proven ability to translate scientific/clinical value into economic value
  • Strong financial acumen, and ability to navigate corporate annual reports and finance documents
  • Ability to efficiently craft and accurately articulate access strategy to senior, cross functional, stakeholders with potentially limited understanding of the access environment in a particular disease area
  • Solid understanding of clinical trial design, health economic models and cost effectiveness, formal certification in HEOR a plus
  • Demonstrated ability to establish unmet needs and drive value perception
  • Knowledge of the product development and commercialization process
  • Ability to travel to international congresses and BMS internal meetings
  • Demonstration of all BMS Behaviors, including Accountability, Innovation, Passion & Urgency
  • Proven experience leveraging and/or implementing, AI-driven insights and digital tools to enhance customer engagement strategies, optimize HCP/patient experience, and drive data-informed commercial decision-making.
Responsibilities
  • To develop worldwide market access strategies and access advice for Oncology products through: evaluating payer insights/perspectives; assessing payer appropriateness of clinical development programs, and recommending modifications to these programs if appropriate; influencing brand strategies based on access, pricing, and HEOR insights; due diligence on business development opportunities (when existing disease area knowledge is required); and leading cross functional teams in a matrixed organization, by both participation, and by leading a teams of Senior Directors, who in turn have teams of PASLs.
  • Development of strong payer value propositions articulating bold and differentiated messages on clinical, humanistic and economic benefits, and that those propositions are supported by strong evidence coming from registrational trials, non-registrational trials, and real-world evidence in appropriate timelines for the worldwide brand / indication launch.
  • Working with BMS HEOR and regulatory teams to seek optimal PRO claims in the product label as appropriate and maximize the economic value of assets.
  • Monitor competitive environment in partnership with the Business Insights team and update cross functional teams on important access developments.
Desired Qualifications
  • Familiarity with top KOLs and their clinical beliefs in the core disease areas a plus
  • Formal certification in HEOR a plus

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Opdivo and Eliquis remain dominant growth drivers with expanding indications and global uptake.
  • AI‑driven clinical trial optimization and regulatory writing can materially shorten development timelines and boost success rates.
  • The Texas plant and AI‑enabled operations position BMS to lower costs and scale new launches efficiently.

What critics are saying

  • Heavy reliance on Eliquis, Opdivo, and Revlimid exposes BMS to abrupt revenue erosion from generics or pricing pressure.
  • Pipeline dependence on mezigdomide and izalontamab brengitecan creates binary downside if late‑stage data disappoints.
  • Enterprise‑scale AI deployment in regulated functions raises compliance and operational risk if outputs are inaccurate or poorly governed.

What makes Bristol Myers Squibb unique

  • Bristol Myers Squibb combines a deep oncology franchise with leading cardiovascular and immunology assets.
  • The company is embedding enterprise‑wide AI into R&D, manufacturing, and regulatory workflows via Anthropic and NVIDIA.
  • BMS is building a next‑generation manufacturing footprint in Texas to support long‑term supply and localization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bristol Myers Squibb who can refer or advise you

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Pharma Focus Asia
May 21st, 2026
Bristol Myers Squibb enters into agreement with Anthropic for AI deployment across global operations.

Bristol Myers Squibb enters into agreement with Anthropic for AI deployment across global operations. Thursday, May 21, 2026 Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy Claude Enterprise across its global operations. The partnership aims to strengthen the use of artificial intelligence in research, clinical development, manufacturing, commercial activities, and corporate functions. The company plans to provide Claude's AI capabilities to more than 30,000 employees. The initiative is designed to move beyond basic chatbot applications and introduce agentic AI systems that can support everyday workflows and decision-making across the organisation. As part of the agreement, Bristol Myers Squibb will use Claude Code to support engineering and data science teams in accelerating software and AI development. The company expects this approach to improve the integration of data and expertise currently spread across disconnected systems. The collaboration will also focus on embedding AI agents into key pharmaceutical workflows. In research, AI tools will be used to analyse scientific, molecular, and clinical data to support target identification and optimisation in areas including oncology, haematology, neuroscience, and immunology. In drug development, the company plans to apply intelligent automation to activities such as preparing clinical study reports, patient safety narratives, and regulatory submissions. The aim is to reduce the time required between clinical data completion and regulatory filing. Manufacturing and quality operations will also benefit from AI-driven support for root-cause investigations, corrective and preventive action documentation, and batch release decisions. The company expects these improvements to strengthen compliance, speed up decision-making, and support faster medicine delivery. In commercial and medical affairs, the technology will help organise field insights into structured information to improve engagement with healthcare professionals and deliver more relevant information when needed. Claude will also be connected to internal systems and repositories containing scientific, clinical, regulatory, and commercial knowledge. Bristol Myers Squibb stated that the deployment will operate with enterprise governance and audit controls. The agreement builds on more than three years of AI investment by Bristol Myers Squibb. The company has already provided employees with access to multiple frontier AI models through its internal AI platform as part of a broader multi-vendor strategy.

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

INACTIVE